There are currently 1474 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Register for Updates
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
NCT06234462
Recruiting
Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
05/07/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Long COVID, Post-Acute COVID-19 Syndrome
Register for Updates
A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.
NCT06481150
Recruiting
This pilot study is proposing a novel approach to directly target intestinal oxalate absorption with the drug Tenapanor, which was recently FDA-approved for treating hyperphosphatemia in patients with chronic kidney disease. Tenapanor works by blocking paracellular phosphate absorption by the intestine, but the underlying mechanisms have not been clearly defined. Since phosphate and oxalate ions are absorbed through the same paracellular pathway, and are of similar size and charge, Tenapanor is... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/07/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hyperoxaluria
Register for Updates
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142
Recruiting
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.
Gender:
MALE
Ages:
1 year and above
Trial Updated:
05/07/2025
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
NCT06076642
Recruiting
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035). The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the d... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/07/2025
Locations: Allergy Partners of North Texas, Dallas, Texas
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: Neurology Consultants of Dallas, PA, Dallas, Texas
Conditions: Focal Epilepsy
Register for Updates
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT06651580
Recruiting
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/07/2025
Locations: University of Texas Southwestern/Children's Medical Center, Dallas, Texas
Conditions: Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis
Register for Updates
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
NCT04678427
Recruiting
This clinical trial studies how well an exercise program (Totally Excited About Moving, Mobility, and Exercise \[TEAM Me\]) affects the exercise and dietary habits of pediatric and adolescents and young adults with cancer undergoing a blood stem cell transplant. TEAM Me is an exercise program that reinforces behavior, such as walking and other activities, using "tokens" (i.e. stickers) that can be redeemed for rewards. Participating in the exercise program may result in increased physical fitnes... Read More
Gender:
ALL
Ages:
Between 6 years and 29 years
Trial Updated:
05/07/2025
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: University of Texas Southwestern Medical Center (Pediatrics only), Dallas, Texas
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
NCT05762302
Recruiting
This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/07/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Lower Respiratory Tract Infection
Register for Updates
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2025
Locations: Site 44, Dallas, Texas
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140
Recruiting
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Gender:
ALL
Ages:
Between 48 months and 69 months
Trial Updated:
05/06/2025
Locations: Javara, Dallas, Texas
Conditions: Attention-Deficit/Hyperactivity Disorder
Register for Updates